257 related articles for article (PubMed ID: 21111542)
1. Efficacy of vaccination at 4 and 6 weeks in the control of canine parvovirus.
De Cramer KG; Stylianides E; van Vuuren M
Vet Microbiol; 2011 Apr; 149(1-2):126-32. PubMed ID: 21111542
[TBL] [Abstract][Full Text] [Related]
2. Intranasal vaccination of pups with maternally derived antibodies with a modified live canine parvovirus.
Buonavoglia C; Cavalli A; Gravino E; Voigt V; Buonavoglia D; de Caprariis D
Zentralbl Veterinarmed B; 1994 Mar; 41(1):3-8. PubMed ID: 7941844
[TBL] [Abstract][Full Text] [Related]
3. Immunization of pups with maternally derived antibodies to canine parvovirus (CPV) using a modified-live variant (CPV-2b).
Pratelli A; Cavalli A; Normanno G; De Palma MG; Pastorelli G; Martella V; Buonavoglia C
J Vet Med B Infect Dis Vet Public Health; 2000 May; 47(4):273-6. PubMed ID: 10861195
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of two canine parvovirus vaccines for inducing seroconversion in Rottweiler and Doberman pinscher pups with various levels of maternally derived antibodies.
Coyne MJ
Vet Ther; 2000; 1(1):35-42. PubMed ID: 19757563
[TBL] [Abstract][Full Text] [Related]
5. Comparison of selected canine vaccines for their ability to induce protective immunity against canine parvovirus infection.
Larson LJ; Schultz RD
Am J Vet Res; 1997 Apr; 58(4):360-3. PubMed ID: 9099379
[TBL] [Abstract][Full Text] [Related]
6. Intranasal vaccination of pups in the presence of maternally derived antibodies to canine parvovirus (CPV). Evaluation of minimal immunizing dose.
Buonavoglia C; Cavalli A; Tempesta M; Voight V; Buonavoglia D; Corrente M; Sagazio P
New Microbiol; 1995 Oct; 18(4):371-5. PubMed ID: 8590389
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of a low-passage, high-titer modified live canine parvovirus vaccine in pups with maternally derived antibodies.
Hoare CM; DeBouck P; Wiseman A
Vaccine; 1997 Feb; 15(3):273-5. PubMed ID: 9139485
[TBL] [Abstract][Full Text] [Related]
8. Maternally-derived antibodies in pups and protection from canine parvovirus infection.
Decaro N; Campolo M; Desario C; Elia G; Martella V; Lorusso E; Buonavoglia C
Biologicals; 2005 Dec; 33(4):261-7. PubMed ID: 16168665
[TBL] [Abstract][Full Text] [Related]
9. Antibody levels and protection to canine parvovirus type 2.
Elia G; Cavalli A; Cirone F; Lorusso E; Camero M; Buonavoglia D; Tempesta M
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):320-2. PubMed ID: 16316392
[TBL] [Abstract][Full Text] [Related]
10. Response of pups with maternal derived antibody to modified-live canine parvovirus vaccine.
Buonavoglia C; Tollis M; Buonavoglia D; Puccini A
Comp Immunol Microbiol Infect Dis; 1992 Oct; 15(4):281-3. PubMed ID: 1330425
[TBL] [Abstract][Full Text] [Related]
11. Response of puppies to canine-origin parvovirus vaccines.
Carmichael LE; Pollock RV; Joubert JC
Mod Vet Pract; 1984 Feb; 65(2):99-102. PubMed ID: 6328258
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the humoral immune response induced by vaccination for canine distemper and parvovirus: a pilot study.
Vila Nova B; Cunha E; Sepúlveda N; Oliveira M; São Braz B; Tavares L; Almeida V; Gil S
BMC Vet Res; 2018 Nov; 14(1):348. PubMed ID: 30445957
[TBL] [Abstract][Full Text] [Related]
13. Comparative trial of the canine parvovirus, canine distemper virus and canine adenovirus type 2 fractions of two commercially available modified live vaccines.
Bergman JG; Muniz M; Sutton D; Fensome R; Ling F; Paul G
Vet Rec; 2006 Nov; 159(22):733-6. PubMed ID: 17127756
[TBL] [Abstract][Full Text] [Related]
14. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus.
Spibey N; Greenwood NM; Sutton D; Chalmers WS; Tarpey I
Vet Microbiol; 2008 Apr; 128(1-2):48-55. PubMed ID: 18006253
[TBL] [Abstract][Full Text] [Related]
15. Early protection of puppies against canine parvovirus: a comparison of two vaccines.
McCaw DL; Tate D; Dubovi EJ; Johnson JC
J Am Anim Hosp Assoc; 1997; 33(3):244-50. PubMed ID: 9138235
[TBL] [Abstract][Full Text] [Related]
16. Vaccination of dogs with canine parvovirus type 2b (CPV-2b) induces neutralising antibody responses to CPV-2a and CPV-2c.
Wilson S; Illambas J; Siedek E; Stirling C; Thomas A; Plevová E; Sture G; Salt J
Vaccine; 2014 Sep; 32(42):5420-4. PubMed ID: 25148778
[TBL] [Abstract][Full Text] [Related]
17. Three-year rabies duration of immunity in dogs following vaccination with a core combination vaccine against canine distemper virus, canine adenovirus type-1, canine parvovirus, and rabies virus.
Lakshmanan N; Gore TC; Duncan KL; Coyne MJ; Lum MA; Sterner FJ
Vet Ther; 2006; 7(3):223-31. PubMed ID: 17039445
[TBL] [Abstract][Full Text] [Related]
18. Oral administration of modified live canine parvovirus type 2b induces systemic immune response.
Cavalli A; Desario C; Marinaro M; Losurdo M; Camero M; Decaro N; Catella C; Lanave G; Buonavoglia C
Vaccine; 2020 Jan; 38(2):115-118. PubMed ID: 31628031
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of positive antibody test results for canine parvovirus (CPV) and canine distemper virus (CDV) and response to modified live vaccination against CPV and CDV in dogs entering animal shelters.
Litster A; Nichols J; Volpe A
Vet Microbiol; 2012 May; 157(1-2):86-90. PubMed ID: 22261239
[TBL] [Abstract][Full Text] [Related]
20. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant?
Larson LJ; Schultz RD
Vet Ther; 2008; 9(2):94-101. PubMed ID: 18597247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
